利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

69 条记录 (耗时 0.038 秒)

    Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
    5.
    发明申请
    Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) 审中-公开
    预防急性和延迟化疗引起的恶心呕吐（CINV）的方法

    公开(公告)号：US20070265329A1

    公开(公告)日：2007-11-15

    申请号：US11433917

    申请日：2006-05-12

    申请人： Shah Devang ,  John Barr ,  Brian Baxter ,  Jorge Heller

    发明人： Shah Devang ,  John Barr ,  Brian Baxter ,  Jorge Heller

    IPC分类号： A61K31/405

    CPC分类号： A61K9/0019 ,  A61K9/08 ,  A61K31/405 ,  A61K47/14 ,  A61K47/34

    摘要： A pharmaceutical composition for the sustained release of an effective amount of a selective 5-hydroxytryptamine 3 (5-HT3) receptor antagonist for the prevention, reduction or alleviation of acute and delayed chemotherapy-induced nausea and vomiting (CINV) following a course of emetogenic chemotherapy, wherein the composition is administered by subcutaneous injection, the composition comprising a 5-HT3 receptor antagonist, a semi-solid delivery vehicle and a pharmaceutically acceptable liquid excipient; wherein the composition, when administered in a single dosage, provides a controlled release of the 5-HT3 receptor antagonist and prolonging the release of the 5-HT3 receptor antagonist that tracks the profile of the incidence of vomiting.

    摘要翻译： 用于持续释放有效量的选择性5-羟色胺3（5-HT 3 N）受体拮抗剂用于预防，减少或缓解急性和延迟化疗引起的恶心和呕吐的药物组合物 （CINV），其中所述组合物通过皮下注射施用，所述组合物包含5-HT 3受体拮抗剂，半固体递送载体和药学上可接受的液体赋形剂; 其中当以单一剂量施用时，所述组合物提供5-HT 3受体拮抗剂的受控释放并延长5-HT 3受体拮抗剂的释放，所述5-HT 3受体拮抗剂的释放 跟踪呕吐发生的概况。

    System and method for transdermal drug delivery
    9.
    发明授权
    System and method for transdermal drug delivery 失效
    用于透皮给药的系统和方法

    公开(公告)号：US5028435A

    公开(公告)日：1991-07-02

    申请号：US355718

    申请日：1989-05-22

    申请人： Martin Katz ,  Sergio Nacht ,  Jorge Heller

    发明人： Martin Katz ,  Sergio Nacht ,  Jorge Heller

    IPC分类号： A61K9/70

    CPC分类号： A61K9/7023

    摘要： Transdermal drug delivery systems comprise a backing or enclosure having a matrix layer which incorporates a drug and a percutaneous enhancer for the drug. The percutaneous enhancer and/or drug will be contained within polymeric particles dispersed through the matrix layer, where the polymeric particles define pore networks which are sized to release the enhancer and/or drug into the matrix layer at rate(s) selected to provide for a desired rate of drug penetration. By isolating the enhancer within the polymeric particles, adverse interactions between the enhancer and the matrix layer and/or the drug can be minimized. Moreover, the release rate of the enhancer into the matrix layer can be carefully controlled, which in turn controls the penetration rate of the drug into the treated host.

    Polyacetal and polyketal hydrogels formed from acetals or ketals and polyols
    10.
    发明授权
    Polyacetal and polyketal hydrogels formed from acetals or ketals and polyols 失效
    由缩醛或缩酮和多元醇形成的聚缩醛和聚缩酮水凝胶

    公开(公告)号：US4898928A

    公开(公告)日：1990-02-06

    申请号：US164604

    申请日：1988-03-07

    申请人： Jorge Heller ,  Donald W. H. Penhale ,  Steve Y. Ng

    发明人： Jorge Heller ,  Donald W. H. Penhale ,  Steve Y. Ng

    IPC分类号： C08G4/00

    CPC分类号： C08G4/00

    摘要： Water-soluble polyacetal or polyketal having the formula ##STR1## wherein R.sub.1, and R.sub.2 are aliphatic, cycloaliphatic or aromatic groups, for ketals; R.sub.1 is hydrogen and R.sub.2 is aliphatic, cycloaliphatic, or aromatic groups for acetals; R.sub.3 and R.sub.4 are also aliphatic, alkoxy, cycloaliphatic or aromatic groups X represents groups as (CH.sub.2).sub.n, O(CH.sub.2).sub.N O or ##STR2## that connect the pendant unsaturation to the aliphatic, cycloaliphatic or aromatic R.sup.4 groups, the ratio of a to b is 0.5 to 10, and n is 10-100.

    摘要翻译： 具有式“IMAGE”的水溶性聚缩醛或聚缩酮，其中R1和R2是脂肪族，脂环族或芳族基团，用于缩酮; R1是氢，R2是用于缩醛的脂族，脂环族或芳族基团; R 3和R 4也是脂族，烷氧基，脂环族或芳族基团X表示将侧基不饱和键连接到脂肪族，脂环族或芳族R 4基团上的（CH 2）n，O（CH 2）NO或 b为0.5〜10，n为10〜100。